Zokinvy

Chemical Namelonafarnib
Dosage FormCapsules (oral; 50mg, 75mg)
Drug ClassInhibitors
SystemSkin, Cardiovascular, Musculoskeletal
CompanyEiger Biopharmaceuticals, Inc.
Approval Year2020

Indication

  • For the treatment of patients 12 months of age and older with a body surface area of 0.39 m2 and above to reduce risk of mortality in Hutchinson-Gilford Progeria Syndrome
  • For treatment of processing-deficient progeroid laminopathies with heterozygous LMNA mutation with progerin-like protein accumulation
  • For treatment of processing-deficient progeroid laminopathies with homozygous or compound heterozygous ZMPSTE24 mutations
Last updated on 12/18/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zokinvy (lonafarnib) Prescribing Information. 2020Eiger Biopharmaceuticals, Inc., Palo Alto, CA